GBP2 and breast carcinoma: Also, in the cohorts of GSE126044 (non-small cell lung cancer), GSE176307 (urothelial carcinoma), PRJEB23709 (melanoma), and MEDI4736 (breast cancer), GBP2 was substantially expressed in tumors with good immunotherapeutic response (Fig. 6D-G).